Treadwell Therapeutics

Treadwell Therapeutics is a clinical oncology company dedicated to developing first-in-class small molecule anticancer drugs by targeting the vulnerabilities of cancer cells to meet the needs of cancer patients. The Treadwell Therapeutics team has developed the first-in-class PLK4 kinase inhibitor CFI-400945 and the potential TTK inhibitor CFI-402257. Treadwell also possesses a robust preclinical pipeline with multiple autologous cell therapy programs based on bio- and next-generation TCR technologies.